支链氨基酸（BCAA）在肝病患者肝脏干预后的益处仍不清楚。我们进行了系统回顾和荟萃分析，评估BCAA对接受肝切除术、经动脉栓塞治疗、射频消融治疗的患者的影响。相关的随机对照试验（RCTs）从PubMed、EMBASE和Cochrane图书馆数据库中获取。我们使用随机效应模型进行荟萃分析，计算汇总效应大小。主要结果是生存率和肿瘤复发率。次要结果是住院时间、营养状况、生化指标、肝脏治疗并发症率和BCAA补充的不良反应。总共包括11个RCTs，涉及750名患者。我们的荟萃分析显示，BCAA组与对照组的肿瘤复发率和总体生存率没有显著差异。然而，汇总估计显示，在进行肝脏干预的患者中，BCAA补充在6个月时明显增加了血清白蛋白（平均差异[MD]：0.11 g/dL，95%置信区间[CI]：0.02-0.20；5个RCTs），并在12个月时显著增加了胆碱酯酶水平（MD：50.00 U/L，95% CI：21.08-78.92；1个RCT），同时降低了12个月时腹水发生率（风险比：0.39，95% CI：0.21-0.71；4个RCTs）与对照组相比。此外，BCAA补充在6个月和12个月时显著增加体重，并在12个月时增加了臂围。综上所述，BCAA补充显著改善了肝功能，减少了腹水发生率，增加了体重和臂围。因此，对于接受肝脏干预的特定患者，BCAA补充可能有益处。

The benefits of branched-chain amino acid (BCAA) administration after hepatic intervention in patients with liver diseases remains unclear. We conducted a systematic review and meta-analysis to evaluate the effects of BCAA on patients undergoing hepatectomy, trans-arterial embolization, radiofrequency ablation. Relevant randomized controlled trials (RCTs) were obtained from PubMed, EMBASE, and Cochrane Library databases. A meta-analysis was performed to calculate the pooled effect size by using random-effects models. The primary outcomes were survival and tumor recurrence. The secondary outcomes were hospital stay, nutrition status, biochemistry profile, complication rate of liver treatment, and adverse effect of BCAA supplementation. In total, 11 RCTs involving 750 patients were included. Our meta-analysis showed no significant difference in the rates of tumor recurrence and overall survival between the BCAA and control groups. However, the pooled estimate showed that BCAA supplementation in patients undergoing hepatic intervention significantly increased serum albumin (mean difference [MD]: 0.11 g/dL, 95% confidence interval [CI]: 0.02-0.20; 5 RCTs) at 6 months and cholinesterase level (MD: 50.00 U/L, 95% CI: 21.08-78.92; 1 RCT) at 12 months, and reduced ascites incidence (risk ratio: 0.39, 95% CI: 0.21-0.71; 4 RCTs) at 12 months compared with the control group. Additionally, BCAA administration significantly increased body weight at 6 months and 12 months, and increased arm circumference at 12 months. In conclusion, BCAA supplementation significantly improved the liver function, reduced the incidence of ascites, and increased body weight and arm circumference. Thus, BCAA supplementation may beneficial for selected patients undergoing liver intervention.